Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Invasive Breast Cancer
Interventions: DRUG: Vandetanib|OTHER: Placebo
Sponsor: Ronald Weigel
Collaborators: AstraZeneca